Trillium Therapeutic (TRIL)
| MRQ (2021-9-30) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 93.23M | 247.60M | 14.60M | 15.30M | 22.50M | |||
| Marketable Securities | 157.45M | 43.60M | 8.10M | 18.10M | 42.50M | |||
| Receivables | 1.51M | 900.00K | 300.00K | 800.00K | 500.00K | |||
| Other Current Assets | 10.88M | 6.40M | 300.00K | 800.00K | 800.00K | |||
| Total Current Assets | 263.07M | 298.50M | 23.30M | 35.00M | 66.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.50M | 1.50M | 2.30M | 1.60M | 2.30M | |||
| Intangibles | 783.00K | 800.00K | 800.00K | 4.20M | 6.40M | |||
| Other Non-Current Assets | N/A | N/A | N/A | 100.00K | 100.00K | |||
| Total Non-Current Assets | 2.29M | 2.30M | 3.10M | 5.80M | 8.80M | |||
| TOTAL ASSETS | 265.36M | 300.80M | 26.40M | 40.80M | 75.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 14.60M | 9.60M | 11.90M | 8.30M | N/A | |||
| Accounts Payable | 1.39M | 7.90M | 1.60M | 500.00K | N/A | |||
| Other Current Liabilities | 5.87M | 3.90M | 13.40M | 1.00M | 300.00K | |||
| Total Current Liabilities | 21.86M | 21.40M | 26.90M | 9.80M | 11.50M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | |||
| Other Non-Current Liabilities | 343.00K | 600.00K | 800.00K | 400.00K | 1.00M | |||
| Total Non-Current Liabilities | 343.00K | 600.00K | 800.00K | 400.00K | 1.10M | |||
| TOTAL LIABILITIES | 22.20M | 22.00M | 27.70M | 10.20M | 12.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -297.95M | -244.40M | -190.00M | -149.30M | -107.50M | |||
| Additional Paid In Capital | 41.41M | 38.60M | 23.10M | 21.00M | 12.10M | |||
| Common Shares | 507.45M | 492.30M | 173.20M | 167.10M | 157.90M | |||
| Other Shareholders' Equity | -7.75M | -7.60M | -7.60M | -8.20M | N/A | |||
| Shares Outstanding | 105.00M | 102.90M | 28.90M | 14.70M | 13.10M | |||
| Tangible Book Value per Share | 2.16 | 2.55 | -0.90 | -0.76 | 1.08 | |||
| Total Shareholders' Equity | 243.16M | 278.80M | -1.30M | 30.60M | 62.50M | |||
| TOTAL LIABILITIES AND EQUITY | 265.36M | 300.80M | 26.40M | 40.80M | 75.10M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.00 | |||
| Current Ratio | 12.04 | 13.95 | 0.87 | 3.57 | 5.77 | |||
| Return On Assets (ROA) | -21.06% | -19.73% | -144.24% | -80.56% | -46.27% | |||
| Return On Equity (ROE) | -22.99% | -21.29% | N/A | -107.42% | -55.60% | |||
All data in USD